Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

7/15/24 5:15:58 PM ET

Medical/Dental Instruments

Health Care

Get the next $BVS alert in real time by email

SC 13G/A 1 d864688dsc13ga.htm SC 13G/A SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)*

Bioventus Inc.

(Name of Issuer)

CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE

(Title of Class of Securities)

09075A108

(CUSIP Number)

July 3, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


CUSIP No. 09075A108		SCHEDULE 13G		Page 2 of 16 Pages


1.		NAMES OF REPORTING PERSONS AMP-CF Holdings, LLC
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON OO


CUSIP No. 09075A108		SCHEDULE 13G		Page 3 of 16 Pages


1.		NAMES OF REPORTING PERSONS Ampersand CF Limited Partnership
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON PN


CUSIP No. 09075A108		SCHEDULE 13G		Page 4 of 16 Pages


1.		NAMES OF REPORTING PERSONS AMP-CF Management Company Limited Partnership
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON PN


CUSIP No. 09075A108		SCHEDULE 13G		Page 5 of 16 Pages


1.		NAMES OF REPORTING PERSONS AMP-CF MC LLC
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON OO


CUSIP No. 09075A108		SCHEDULE 13G		Page 6 of 16 Pages


1.		NAMES OF REPORTING PERSONS Ampersand 2020 Limited Partnership
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON PN


CUSIP No. 09075A108		SCHEDULE 13G		Page 7 of 16 Pages


1.		NAMES OF REPORTING PERSONS AMP-20 Management Company Limited Partnership
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON PN


CUSIP No. 09075A108		SCHEDULE 13G		Page 8 of 16 Pages


1.		NAMES OF REPORTING PERSONS AMP-20 MC LLC
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON OO


CUSIP No. 09075A108		SCHEDULE 13G		Page 9 of 16 Pages


1.		NAMES OF REPORTING PERSONS Herbert H. Hooper
2.		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☒
3.		SEC USE ONLY
4.		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH				5.		SOLE VOTING POWER 0
				6.		SHARED VOTING POWER 0
				7.		SOLE DISPOSITIVE POWER 0
				8.		SHARED DISPOSITIVE POWER 0


9.		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0
10.		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ☐
11.		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0%
12.		TYPE OF REPORTING PERSON IN


CUSIP No. 09075A108		SCHEDULE 13G		Page 10 of 16 Pages

Item 1.

Issuer

(a)

Name of Issuer:

Bioventus Inc. (the “Issuer”)

(b)

Address of Issuer’s Principal Executive Offices:

4721 Emperor Boulevard, Suite 100

Durham, NC 27703

Item 2.

Filing Person

(a) – (c) Name of Persons Filing; Address; Citizenship:

AMP-CF Holdings, LLC

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware

Ampersand CF Limited Partnership

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware

AMP-CF Management Company Limited Partnership

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware

AMP-CF MC LLC

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware

Ampersand 2020 Limited Partnership

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware

AMP-20 MC LLC

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware

AMP-20 Management Company Limited Partnership

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Place of Organization: Delaware


CUSIP No. 09075A108		SCHEDULE 13G		Page 11 of 16 Pages

Hooper, Herbert H

C/O Ampersand Capital Partners

55 William Street, Suite 240

Wellesley, Ma 02481

Citizenship: United States

(d)

Title of Class of Securities:

Class A common stock, par value $0.001 per share (“Class A Common Stock”)

(e)

CUSIP Number:

09075A108

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

See response to Item 9 on each cover page.

(b)

See response to Item 11 on each cover page

(c)

(i) See response to Item 5 on each cover page

(ii)	See response to Item 6 on each cover page

(iii)

See response to Item 7 on each cover page

(iv)	See response to Item 8 on each cover page

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☒

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.


CUSIP No. 09075A108		SCHEDULE 13G		Page 12 of 16 Pages

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

The Reporting Persons expressly disclaim membership in a “group” as used in Rule 13d-5(b)(1).

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 09075A108		SCHEDULE 13G		Page 13 of 16 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


AMP-CF Holdings, LLC								Date:

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer


Ampersand CF Limited Partnership
By AMP-CF Management Company Limited Partnership, its general partner
By: AMP-CF MC LLC, its general partner

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer


AMP-CF Management Company Limited Partnership By: AMP-CF MC LLC, its general partner

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer


AMP-CF MC LLC

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer


Ampersand 2020 Limited Partnership
By: AMP-20 Management Company Limited Partnership
By: AMP-20 MC LLC, its general partner

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer


AMP-20 Management Company Limited Partnership
By: AMP-20 MC LLC, its general partner

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer


CUSIP No. 09075A108		SCHEDULE 13G		Page 14 of 16 Pages


AMP-20 MC LLC

By:		/s/ Dana L. Niles						7/15/2024
Name:		Dana L. Niles
Title:		Chief Operating Officer

/s/ Herbert H. Hooper
Herbert H. Hooper								7/15/2024

Get the next $BVS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BVS

Date	Price Target	Rating	Analyst
12/17/2024	$12.00 → $13.00	Underweight → Neutral	Analyst
12/7/2023	$7.00	Hold → Buy	Canaccord Genuity
8/9/2023	$4.00 → $6.00	Hold → Buy	Craig Hallum
11/22/2022		Buy → Hold	Craig Hallum
11/9/2022	$18.00 → $6.00	Buy → Hold	Canaccord Genuity
11/9/2022		Overweight → Underweight	JP Morgan
3/15/2022	$30.00	Buy	Craig Hallum
3/11/2022	$20.00 → $18.00	Overweight	Morgan Stanley

More analyst ratings

Apyx Medical Corporation Announces Board Leadership Transition
Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead
5/9/24 7:00:00 AM ET
$APYX
$BVS
$XTNT
Medical/Dental Instruments
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Bioventus Appoints Mark Singleton as Chief Financial Officer
DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si
2/28/22 7:00:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus Appoints Michelle McMurry-Heath to Board of Directors
DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex
12/21/21 9:25:00 AM ET
$BVS
Medical/Dental Instruments
Health Care

$BVS
Press Releases

Fastest customizable press release news feed in the world

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website
4/28/25 8:00:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs
2/28/25 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives.
1/7/25 8:00:00 AM ET
$BVS
Medical/Dental Instruments
Health Care

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025
DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website
4/28/25 8:00:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs
2/28/25 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024
DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web
10/29/24 7:30:00 AM ET
$BVS
Medical/Dental Instruments
Health Care